BACKGROUND mChT consists on the administration of repetitive, low doses of
chemotherapy drugs and represents an attractive and active therapeutic strategy in cancer …

Background Patients with MBC prefer convenient treatments with low toxicity but without
compromised efficacy. Metronomic chemotherapy (MCT), which involves oral low dose …

Purpose Metronomic combination chemotherapy with the oral fluoropyrimidine
doxifluridine/5′-deoxy-5-fluorouridine (5-DFUR) and oral cyclophosphamide (C) showed …

Introduction Metronomic chemotherapy (mCHT) is a treatment regimen in which drugs are
administered frequently or continuously and that maintains low, prolonged, and …

Purpose Capecitabine is effective against metastatic breast cancer (MBC). We hypothesized
that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and …

Introduction Metronomic chemotherapy (MCT) is the continuous administration of low dose
chemotherapy. It has significant clinical efficacy with minimal toxicity as compared to …

e12552 Background: mCHT is the minimum biologically effective dose of a
chemotherapeutic agent, given at regular dosing regimen with no prolonged drug free …

1086 Background: The approved capecitabine (X) regimen in MBC is 1,250 mg/m2 bid, d1–
14 q21d (Xint). However, dose modifications are often required primarily for hand-foot …

e11567 Background: Low-dose metronomic chemotherapy is an emergent treatment
schedule in which low doses of cytotoxic agents are given orally continuously, with no or …

Background Real‐world data of the CM regimen [cyclophosphamide (CTX) plus
methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small …